These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 32382945

  • 1. [99cmTc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center.
    Werner P, Neumann C, Eiber M, Wester HJ, Schottelius M.
    EJNMMI Res; 2020 May 07; 10(1):45. PubMed ID: 32382945
    [Abstract] [Full Text] [Related]

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 May 07; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 3. PSMA SPECT/CT with 99mTc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels.
    Schmidkonz C, Goetz TI, Kuwert T, Ritt P, Prante O, Bäuerle T, Goebell P, Cordes M.
    Ann Nucl Med; 2019 Dec 07; 33(12):891-898. PubMed ID: 31502084
    [Abstract] [Full Text] [Related]

  • 4. An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study.
    Ora M, Saini VK, Dixit M, Singh UP, Gambhir S.
    Indian J Nucl Med; 2024 Dec 07; 39(3):170-176. PubMed ID: 39291065
    [Abstract] [Full Text] [Related]

  • 5. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial.
    Zhang Y, Lin Z, Li T, Wei Y, Yu M, Ye L, Cai Y, Yang S, Zhang Y, Shi Y, Chen W.
    Sci Rep; 2022 Sep 26; 12(1):15993. PubMed ID: 36163353
    [Abstract] [Full Text] [Related]

  • 6. Diagnostic value of [99mTc]Tc-PSMA-I&S-SPECT/CT for the primary staging and restaging of prostate cancer.
    Farkas I, Sipka G, Bakos A, Maráz A, Bajory Z, Mikó Z, Czékus T, Urbán S, Varga L, Pávics L, Besenyi Z.
    Ther Adv Med Oncol; 2024 Sep 26; 16():17588359231221342. PubMed ID: 38249326
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT.
    Lawal IO, Ankrah AO, Mokgoro NP, Vorster M, Maes A, Sathekge MM.
    Prostate; 2017 Aug 26; 77(11):1205-1212. PubMed ID: 28649735
    [Abstract] [Full Text] [Related]

  • 8. Delayed Imaging Improves Lesion Detectability in [99mTc]Tc-PSMA-I&S SPECT/CT in Recurrent Prostate Cancer.
    Berliner C, Steinhelfer L, Chantadisai M, Kroenke M, Koehler D, Pose R, Bannas P, Knipper S, Eiber M, Maurer T.
    J Nucl Med; 2023 Jul 26; 64(7):1036-1042. PubMed ID: 37230531
    [Abstract] [Full Text] [Related]

  • 9. [99mTc]Tc-HYNIC-ALUG SPECT/CT in the initial staging of 227 consecutive patients with newly diagnosed prostate cancer: a 5-year monocentric retrospective study.
    Li B, Ding X, Duan L, Shi J, Tang M, Zhang J, Zhao Z, Wu X, Gao Y.
    Front Endocrinol (Lausanne); 2024 Jul 26; 15():1326858. PubMed ID: 38449842
    [Abstract] [Full Text] [Related]

  • 10. An Australian experience using Tc-PSMA SPECT/CT in the primary diagnosis of prostate cancer and for staging at biochemical recurrence after local therapy.
    Duncan I, Ingold N, Martinez-Marroquin E, Paterson C.
    Prostate; 2023 Jul 26; 83(10):970-979. PubMed ID: 37051636
    [Abstract] [Full Text] [Related]

  • 11. 99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
    Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
    Prostate; 2018 Jan 26; 78(1):54-63. PubMed ID: 29105797
    [Abstract] [Full Text] [Related]

  • 12. A prospective intra-individual comparison of [68Ga]Ga-PSMA-11 PET/CT, [68Ga]Ga-NODAGAZOL PET/CT, and [99mTc]Tc-MDP bone scintigraphy for radionuclide imaging of prostate cancer skeletal metastases.
    Lawal IO, Mokoala KMG, Mahapane J, Kleyhans J, Meckel M, Vorster M, Ebenhan T, Rösch F, Sathekge MM.
    Eur J Nucl Med Mol Imaging; 2021 Jan 26; 48(1):134-142. PubMed ID: 32424485
    [Abstract] [Full Text] [Related]

  • 13. A Prospective Comparison of 18F-prostate-specific Membrane Antigen-1007 Positron Emission Tomography Computed Tomography, Whole-body 1.5 T Magnetic Resonance Imaging with Diffusion-weighted Imaging, and Single-photon Emission Computed Tomography/Computed Tomography with Traditional Imaging in Primary Distant Metastasis Staging of Prostate Cancer (PROSTAGE).
    Anttinen M, Ettala O, Malaspina S, Jambor I, Sandell M, Kajander S, Rinta-Kiikka I, Schildt J, Saukko E, Rautio P, Timonen KL, Matikainen T, Noponen T, Saunavaara J, Löyttyniemi E, Taimen P, Kemppainen J, Dean PB, Blanco Sequeiros R, Aronen HJ, Seppänen M, Boström PJ.
    Eur Urol Oncol; 2021 Aug 26; 4(4):635-644. PubMed ID: 32675047
    [Abstract] [Full Text] [Related]

  • 14. Preclinical Evaluation and First Patient Application of 99mTc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer.
    Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ.
    J Nucl Med; 2017 Feb 26; 58(2):235-242. PubMed ID: 27635024
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic Performance of 99mTc-iPSMA SPECT/CT in the Initial Staging of Patients with Unfavorable Intermediate-, High-, and Very High-Risk Prostate Cancer: A Comparative Analysis with 18F-PSMA-1007 PET/CT.
    Vargas-Ahumada JE, González-Rueda SD, Sinisterra-Solís FA, Casanova-Triviño P, Pitalúa-Cortés Q, Soldevilla-Gallardo I, Scavuzzo A, Jimenez-Ríos MA, García-Pérez FO.
    Cancers (Basel); 2023 Dec 13; 15(24):. PubMed ID: 38136369
    [Abstract] [Full Text] [Related]

  • 16. Direct comparison of 99mTc-PSMA SPECT/CT and 68Ga-PSMA PET/CT in patients with prostate cancer.
    Albalooshi B, Al Sharhan M, Bagheri F, Miyanath S, Ray B, Muhasin M, Zakavi SR.
    Asia Ocean J Nucl Med Biol; 2020 Dec 13; 8(1):1-7. PubMed ID: 32064277
    [Abstract] [Full Text] [Related]

  • 17. The efficacy of 99mTc-HYNIC-PSMA SPECT/CT in detecting primary lesions and metastasis in newly diagnosed prostate cancer.
    Wang T, Zhao L, Qiao W, Sun N, Zhao J, Xing Y.
    Front Oncol; 2023 Dec 13; 13():1165694. PubMed ID: 37333816
    [Abstract] [Full Text] [Related]

  • 18. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
    von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.
    Eur Urol Focus; 2018 Sep 13; 4(5):686-693. PubMed ID: 28753806
    [Abstract] [Full Text] [Related]

  • 19. 68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.
    Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.
    Eur J Nucl Med Mol Imaging; 2019 Jan 13; 46(1):31-39. PubMed ID: 30350010
    [Abstract] [Full Text] [Related]

  • 20. 99mTc-PSMA targeted robot-assisted radioguided surgery during radical prostatectomy and extended lymph node dissection of prostate cancer patients.
    Yılmaz B, Şahin S, Ergül N, Çolakoğlu Y, Baytekin HF, Sökmen D, Tuğcu V, Taşçı Aİ, Çermik TF.
    Ann Nucl Med; 2022 Jul 13; 36(7):597-609. PubMed ID: 35426599
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.